SUNDAY, JULY 15, 2018

Kineta vaccine adjuvants improve vaccine protection

Kineta vaccine adjuvants improve vaccine protection
Kineta vaccine adjuvants improve vaccine protection | Courtesy of
Representatives from Kineta, Inc., a biotechnology company that creates immune modulating drugs to treat infectious diseases, recently released data that proves Kineta’s vaccine adjuvants improve the level of protection provided by the vaccine.

These adjuvants may be instrumental in increasing the effectiveness of vaccines, reducing vaccine dosages and boosting cross protection.

Kineta researchers discovered the molecules by using the company’s proprietary AViid discovery platform. This platform uses the small adjuvant molecules to create immune pathways dependent on the IRF. The adjuvant system improved the anti-viral cellular immune response as well as the production of antibodies when it was included with the vaccine in Kineta’s animal models.

Adjuvants are molecules that are supplementary to the vaccine and enhance the body’s response to the immune system.

“Our vaccine adjuvants enhance the protection conferred by existing influenza vaccines as demonstrated in lethal mouse infection models, and are also dose sparing and have the potential to strengthen the effectiveness of a variety of vaccines,” Kineta's associate director of program management and virology Chelsea Olsen said. “In addition, unlike conventional vaccine adjuvants, our host directed small molecule compounds stimulate innate antiviral pathways which results in a more specific response." 

Olsen recently presented this information at the World Vaccine Congress.

Organizations in this Story

Kineta, Inc.

Want to get notified whenever we write about Kineta, Inc. ?
Next time we write about Kineta, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.